J&J Hid Topamax Birth Defect Risks, Philly Jury Hears

Law360, Philadelphia (February 24, 2014, 5:55 PM EST) -- A Johnson & Johnson subsidiary failed to adequately warn parents about the risk of birth defects associated with the epilepsy and migraine drug Topamax, an attorney for the family of a 5-year-old boy born with a cleft palate told a Philadelphia jury on Monday.

Scott Love, an attorney with Clark Love & Hutson representing the family of 5-year-old Josiah Brown, told a state jury during opening arguments that the failure of J&J subsidiary Janssen Pharmaceuticals Inc. to provide information to doctors about the possibility of birth...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.